Mylan launches Remdesivir in India for Covid-19 patients.

0
35

Mylan one of the world’s leading global pharmaceutical company commercially launches Remdesivir under the brand name DESREM in India for Covid-19 patients. The medicine is actually approved for the treatment of suspected or laboratory-confirmed cases of Covid-19 in children and adults who are hospitalized with severe symptoms of infection. This drug is actually a generic version of Remdesivir.

The company also launched a helpline wherein patients and healthcare people can get access to the information related to Mylan’s Remdesivir and its availability, across our nation. The helpline is available 24/7 at +91.78299.80066. With the launch of this helpline and DESREM, the company aims to enhance availability to this critical medicine used for treatment in adults and children against the Covid-19 infections.

The first batch of  Remdesivir was launched on the 20th of July by the company. The company added, they shall continue to increase the supply of the drug across the country as the demand rises. The drug is being produced in its injectable facility in Bangalore, India, which will work to fulfill the demand in India and other export markets. In India, Remdesivir has been released by Hetero Labs and Cipla as of now. Mylan believes its there also a responsibility to help make the world a better place and their whole team at Mylan has been working hard to serve patients and deliver better health for a better world.

The company had said before that the drug Remdesivir will be on board from July at a cost of ₹4,800 per 100 mg vial, in India. According to Mylan, India and Emerging Markets, President Rakesh Bamzai, Mylan will remain committed to carrying on its efforts in the fight against the Covid-19 pandemic. Mylan had said earlier that its medicine Remdesivir will be available at a cost of Rs 4,800 per 100 mg vial as against Cipla’s Cipremi costing Rs 4,000 and  Hetero’s Covifor at Rs 5,400 per vial. Mylan and domestic pharma firms like Jubilant Life Sciences, Hetero Labs and Cipla had entered into a non-exclusive licensing agreement with the drug major Gilead Sciences Inc for manufacturing and distribution of Remdesivir in India.

Mylan has received a license from Gilead for the commercialization of the medicine Remdesivir. The drug has been proceeded with an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) to treat Coronavirus infected patients.

LEAVE A REPLY

Please enter your comment!
Please enter your name here